VRX
Valeant Pharmaceuticals International Inc
Valeant Pharmaceuticals International Inc historical holders
total: 14
Meritage Group Valeant Pharmaceuticals International Inc transactions over time
- Total transactions:
- 10
- New positions:
- 1
- Sold out:
- 1
- Added:
- 5
- Reduced:
- 3
- Held since:
- 2013 Q2 or earlier
- Held for:
- 10+ quarters
- Latest activity:
- 2015 Q4
Nathaniel Simons has been an institutional investor in Valeant Pharmaceuticals International Inc (VRX) since at least 2013 Q2. According to 2026 Q1 report, Nathaniel Simons doesn't hold any shares. In our earliest available record from 2013 Q2, Meritage Group held about 1.19M shares of VRX. Since at least 2013 Q2, Meritage Group has made 9 more transactions in this position.
When did Nathaniel Simons exit their VRX position?
Nathaniel Simons no longer holds Valeant Pharmaceuticals International Inc (VRX). They sold off their entire position in 2015 Q4, closing out an investment that began in 2013 Q2.
Estimated cost basis*
- Weighted AVG buy price:
- $110.33
- Weighted AVG sell price:
- $166.02
VRX transactions history by Meritage Group
10 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2015 Q4
|
0.00%
|
$178.38
|
-100% (-1,344,024)
|
|||
|
2015 Q3
|
6.33%
|
$178.38
|
+0.11% (+1,457)
|
|||
|
2015 Q2
|
6.99%
|
$222.15
|
-0.10% (-1,403)
|
|||
|
2015 Q1
|
7.21%
|
$198.62
|
+23.95% (+259,666)
|
|||
|
2014 Q4
|
4.23%
|
$143.11
|
-31.44% (-497,347)
|
|||
|
2014 Q3
|
5.65%
|
$131.20
|
+0.02% (+347)
|
|||
|
2014 Q2
|
5.60%
|
$126.12
|
+15.12% (+207,737)
|
|||
|
2014 Q1
|
5.10%
|
$131.83
|
-10.14% (-155,036)
|
|||
|
2013 Q4
|
5.61%
|
$117.40
|
+28.97% (+343,374)
|
|||
|
2013 Q2
|
3.46%
|
$86.08
|
new or own*
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.